NASDAQ · OCUL
Ocular Therapeutix, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OCUL: Nov 3, 2026
Ocular Therapeutix, Inc. Common Stock is estimated to report earnings on 11/03/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.36. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.36 | $-0.34 | $-0.37 | 6 |
| Dec 2026 | $-0.37 | $-0.35 | $-0.38 | 5 |
| Mar 2027 | $-0.38 | $-0.36 | $-0.39 | 4 |
| Jun 2027 | $-0.37 | $-0.35 | $-0.38 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · BNK Invest · Zacks- MarketBeat · Oct 20, 12:04 PM EDTOcular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 WinOcular Therapeutix (NASDAQ:OCUL) is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with the U.S. Food and Drug Administration, President and Chief Ex
- MarketBeat · Sep 22, 11:02 PM EDTOcular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 SuccessOcular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel described as alignment with the Food and Drug Administration on the company’s plann
- RTTNews · Sep 15, 7:39 AM EDTOcular Therapeutix Reports Positive Pre-NDA Meeting With FDA For AXPAXLI In Wet AMD(RTTNews) – Ocular Therapeutix, Inc. (OCUL), an integrated biopharmaceutical company focused on retinal diseases, announced the successful completion of its Pre-New Drug Application (NDA) Meeting with the U.S. FDA for AXPAXLI, its investigational treatment for wet age-related mac
- BNK Invest · Aug 12, 3:49 PM EDTNotable Wednesday Option Activity: OCUL, LLY, WENAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Ocular Therapeutix Inc (Symbol: OCUL), where a total of 25,374 contracts have traded so far, representing approximately 2.5 million underlying shares. That amounts to ab
- Zacks · Aug 3, 8:10 AM EDTOcular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue EstimatesOcular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- MarketBeat · Jul 22, 8:02 PM EDTOcular Therapeutix Eyes Q4 AXPAXLI NDA After FDA AlignmentOcular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman, President and CEO Dr. Pravin Dugel described as alignment with the U.S. Food and Dr
- RTTNews · Jun 22, 4:29 AM EDTOcular Presents Updates On AXPAXLI NDA For Macular Degeneration At Investor Day Event(RTTNews) – Ocular Therapeutix Inc. (OCLU), a biopharmaceutical company, on Thursday released updates on FDA alignments achieved for the new drug application (NDA) for AXPAXLI in treating wet Age-related Macular Degeneration (wet AMD). The data was presented at an Investors Day,
- The Motley Fool · Jun 15, 4:30 PM EDTOcular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli.
- The Motley Fool · May 26, 6:26 PM EDTAcuta Capital Sells 56% of Ocular Therapeutix Shares in Q1Acuta Capital Partners reduced its Ocular Therapeutix holding by 460,887 shares.
- The Motley Fool · May 19, 1:26 PM EDTWhat This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsSaturn V sold 1,504,880 shares of Ocular Therapeutix in the first quarter; the estimated transaction value was $14.34 million.
- Zacks · May 5, 9:15 AM EDTOcular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesOcular Therapeutix (OCUL) delivered earnings and revenue surprises of -29.46% and -15.29%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · Mar 18, 11:41 AM EDTWhat to Make of VR Adviser's Big Ocular Therapeutix Sell-DownAdviser, LLC Sold 5,845,915 shares of Ocular Therapeutix; estimated transaction value $71.01 million based on quarterly average price.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Ocular Therapeutix, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.